Skip to main content

FOCIS 2019 Virtual Issue

In celebration of The Federation of Clinical Immunology Societies (FOCIS)​ Annual Meeting in Boston (18-21 June), the BSI’s official journal Clinical & Experimental Immunology is pleased to provide free access to a selection of primary research and review articles that relate to topics discussed at FOCIS 2019.

The papers we have chosen complement the FOCIS programme and reflect some of the key advances made in recent years in fields as diverse as cancer immunotherapy, myeloid and stromal cell biology, cytokine therapies, tissue resident immunity, immune metabolism, ageing/immunosenescence, and epigenetics. Some of the papers we highlight are part of our Review Series. These Series are designed to provide researchers with a broad range of in-depth analyses of recent developments in emerging fields of translational immunology, and always prove popular with readers.

Clinical & Experimental Immunology seeks to publish the best translational and clinical immunology studies; those which have the potential to transform our understanding of the immunopathology of human disease, or change clinical practice. Our articles cover basic and clinical investigations regarding the immunological basis of a wide range of human pathologies, including autoimmunity, inflammatory diseases, primary and secondary immunodeficiencies, complement disorders, allergies, infectious diseases, cancer and transplantation rejection, and we favour studies underpinned by strong mechanistic insight. 

If you are interested in submitting an article to Clinical & Experimental Immunology or would like to discuss an idea for a review or review series, our Editor-in-Chief, Professor Leonie Taams, will be available to chat at FOCIS 2019. If you would like to meet with Prof. Taams, please contact imm@immunology.org

We hope you enjoy this collection of articles, and we encourage you to share this with colleagues online using the FOCIS 2019 hashtag #FOCIS and looping in @CEIjournal and @FOCISimmunology

 

 


Figure from Immune checkpoint inhibitors: new strategies to checkmate cancer

Articles relating to Sessions on “Cancer Immunotherapy: Light the Fire” and “Immune Checkpoints: Autoimmunity, Cancer and Infectious Diseases”

Immunotherapies based on PD‐1/PD‐L1 pathway inhibitors in ovarian cancer treatment 
Pawłowska, A., Suszczyk, D., Okła, K., Barczyński, B., Kotarski, J. and Wertel, I. (2019)
Clin Exp Immunol, 195: 334-344. doi:10.1111/cei.13255

Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R. A., Evans, T. R., Fraser, A. R. and Nibbs, R. J. (2018)
Clin Exp Immunol, 191: 133-148. doi:10.1111/cei.13081

In‐vitro effect of pembrolizumab on different T regulatory cell subsets
Toor, S. M., Syed Khaja, A. S., Alkurd, I. and Elkord, E. (2018)
Clin Exp Immunol, 191: 189-197. doi:10.1111/cei.13060

Programmed death‐1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour‐ infiltrating dendritic cells 
Jiao, Q., Liu, C., Li, W., Li, W., Fang, F., Qian, Q. and Zhang, X. (2017)
Clin Exp Immunol, 188: 420-429. doi:10.1111/cei.12921

Inflammatory cytokines compromise programmed cell death‐1 (PD‐1)‐mediated T cell suppression in inflammatory arthritis through up‐regulation of soluble PD‐1
Bommarito, D., Hall, C., Taams, L. S. and Corrigall, V. M. (2017)
Clin Exp Immunol, 188: 455-466. doi:10.1111/cei.12949

Immune deficiency and autoimmunity in patients with CTLA‐4 (CD152) mutations 
Verma, N., Burns, S. O., Walker, L. S. and Sansom, D. M. (2017)
Clin Exp Immunol, 190: 1-7. doi:10.1111/cei.12997

 

 


Articles relating to Session on “Metabolic Control

We are delighted to offer a preview of the published papers for the upcoming Review Series ‘Translating Immunometabolism’, Guest Edited by Sarah Dimeloe and Claudio Mauro.

Translating Immunometabolism
Series Editors: Sarah Dimeloe and Claudio Mauro


Articles relating to Sessions on “Myeloid Cells in Human Disease” and “The Effects of Stromal and Myeloid Cells on Immune Inflammation” 

Figure from The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents?

Driving chronicity in rheumatoid arthritis - perpetuating role of myeloid cells
Alivernini, S., Tolusso, B., Ferraccioli, G., Gremese, E., Kurowska‐Stolarska, M. and McInnes, I. B. (2018)
Clin Exp Immunol, 193: 13-23. doi:10.1111/cei.13098

Stroma: the forgotten cells of innate immune memory
Crowley, T., Buckley, C. D. and Clark, A. R. (2018) 
Clin Exp Immunol, 193: 24-36. doi:10.1111/cei.13149

The role of stromal cells in inflammatory bone loss
Wehmeyer, C., Pap, T., Buckley, C. D. and Naylor, A. J. (2017)
Clin Exp Immunol, 189: 1-11. doi:10.1111/cei.12979 

Adjuvant pretreatment with alum protects neonatal mice in sepsis through myeloid cell activation
Rincon, J. C., Cuenca, A. L., Raymond, S. L., Mathias, B., Nacionales, D. C., Ungaro, R., Efron, P. A., Wynn, J. L., Moldawer, L. L. and Larson, S. D. (2018)
Clin Exp Immunol, 191: 268-278. doi:10.1111/cei.13072

Clinical and functional significance of STEAP4‐splice variant in CD14+ monocytes in patients with rheumatoid arthritis
Ebe, H., Matsumoto, I., Kawaguchi, H., Kurata, I., Tanaka, Y., Inoue, A., Kondo, Y., Tsuboi, H. and Sumida, T. (2018)
Clin Exp Immunol, 191: 338-348. doi:10.1111/cei.13076

The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents? 
Carty, F., Mahon, B. P. and English, K. (2017)
Clin Exp Immunol, 188: 1-11. doi:10.1111/cei.12929 


Articles relating to Sessions on “Cytokine Therapy” and “Next Generation Cytokine Therapies in the Clinic”

IL‐27: a double agent in the IL‐6 family            

Figure from The role of interleukin‐6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis

Jones, G. W., Hill, D. G., Cardus, A. and Jones, S. A. (2018)
Clin Exp Immunol, 193: 37-46. doi:10.1111/cei.13116

The role of interleukin‐6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis 
Schinnerling, K., Aguillón, J. C., Catalán, D. and Soto, L. (2017)
Clin Exp Immunol, 189: 12-20. doi:10.1111/cei.12966
 
Interleukin‐9 and T helper type 9 cells in rheumatic diseases
Ciccia, F., Guggino, G., Ferrante, A., Cipriani, P., Giacomelli, R. and Triolo, G. (2016)
Clin Exp Immunol, 185: 125-132. doi:10.1111/cei.12807

Immunoassay methods used in clinical studies for the detection of anti‐drug antibodies to adalimumab and infliximab 
Gorovits, B., Baltrukonis, D. J., Bhattacharya, I., Birchler, M. A., Finco, D., Sikkema, D., Vincent, M. S., Lula, S., Marshall, L. and Hickling, T. P. (2018)
Clin Exp Immunol, 192: 348-365. doi:10.1111/cei.13112

Low‐dose interleukin‐2 promotes STAT‐5 phosphorylation, Treg survival and CTLA‐4‐dependent function in autoimmune liver diseases 
Jeffery, H. C., Jeffery, L. E., Lutz, P., Corrigan, M., Webb, G. J., Hirschfield, G. M., Adams, D. H. and Oo, Y. H. (2017)
Clin Exp Immunol, 188: 394-411. doi:10.1111/cei.12940


Articles relating to Session on “Tissue Resident Immunity

Tissue‐resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer 
Hartana, C. A., Ahlén Bergman, E., Broomé, A., Berglund, S., Johansson, M., Alamdari, F., Jakubczyk, T., Huge, Y., Aljabery, F., Palmqvist, K., Holmström, B., Glise, H., Riklund, K., Sherif, A. and Winqvist, O. (2018) 
Clin Exp Immunol, 194: 39-53. doi:10.1111/cei.13183

Skin resident memory CD8+ T cells are phenotypically and functionally distinct from circulating populations and lack immediate cytotoxic function 
Seidel, J. A., Vukmanovic‐Stejic, M., Muller‐Durovic, B., Patel, N., Fuentes‐Duculan, J., Henson, S. M., Krueger, J. G., Rustin, M. H., Nestle, F. O., Lacy, K. E. and Akbar, A. N. (2018)
Clin Exp Immunol, 194: 79-92. doi:10.1111/cei.13189


Articles relating to Session on “Aging/Senescence: Immunology of the Ages”

Review Series: Ageing and the immune system, effects of immunosenescence and clinical implications 
Series Editors: Birgit Weinberger and Arne Akbar

Figure from Considerations for successful cancer immunotherapy in aged hosts

 


Articles relating to Session on “Epigenetics to Dissect Immune Cell Identity in Health and Disease”

CRISPR‐based reagents to study the influence of the epigenome on gene expression 
Lavender, P., Kelly, A., Hendy, E. and McErlean, P. (2018)
Clin Exp Immunol, 194: 9-16. doi:10.1111/cei.13190

Selective HDAC6 inhibition decreases early stage of lupus nephritis by down‐regulating both innate and adaptive immune responses
Ren, J., Liao, X., Vieson, M. D., Chen, M., Scott, R., Kazmierczak, J., Luo, X. M. and Reilly, C. M. (2018) 
Clin Exp Immunol, 191: 19-31. doi:10.1111/cei.13046

AID and TET2 co‐operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma 
Jiao, J., Jin, Y., Zheng, M., Zhang, H., Yuan, M., Lv, Z., Odhiambo, W., Yu, X., Zhang, P., Li, C., Ma, Y. and Ji, Y. (2019)

Figure from CRISPR‐based reagents to study the influence of the epigenome on gene expression

Clin Exp Immunol, 195: 190-201. doi:10.1111/cei.13227

HDAC inhibitors modulate innate immune responses to micro‐organisms relevant to chronic mucocutaneous candidiasis 
Rösler, B., Wang, X., Keating, S. T., Joosten, L. A., Netea, M. G. and Veerdonk, F. L. (2018)
Clin Exp Immunol, 194: 205-219. doi:10.1111/cei.13192

DNA methylation alterations in the pathogenesis of lupus 
Chen, S. H., Lv, Q. L., Hu, L., Peng, M. J., Wang, G. H. and Sun, B. (2017)
Clin Exp Immunol, 187: 185-192. doi:10.1111/cei.12877

 


Clinical & Experimental Immunology and Immunology are the official journals of the British Society for Immunology. Profits derived from the sale of the journals are invested back into the BSI, providing major financial support for the Society's activities. 

Support the BSI, submit your work now:

Clinical & Experimental Immunology

Immunology